BACKGROUND: We wished to identify noninvasive in vivo biomarkers of brain energy deficit in Huntington disease. METHODS: We studied 15 early affected patients (mean motor United Huntington Disease Rating Scale, 18 ± 9) and 15 age- and sex-matched controls. We coupled (31)phosphorus nuclear magnetic resonance spectroscopy with activation of the occipital cortex in order to measure the relative concentrations of adenosine triphosphate, phosphocreatine, and inorganic phosphate before, during, and after visual stimulation. RESULTS: In controls, we observed an 11% increase in the inorganic phosphate/phosphocreatine ratio (P = .024) and a 13% increase in the inorganic phosphate/adenosine triphosphate ratio (P = .016) during brain activation, reflecting increased adenosine diphosphate concentrations. Subsequently, controls had a return to baseline levels during recovery (P = .012 and .022, respectively). In contrast, both ratios were unchanged in patients during and after visual stimulation. CONCLUSIONS: (31)Phosphorus nuclear magnetic resonance spectroscopy could provide functional biomarkers of brain energy deficit to monitor therapeutic efficacy in Huntington disease.
BACKGROUND: We wished to identify noninvasive in vivo biomarkers of brain energy deficit in Huntington disease. METHODS: We studied 15 early affected patients (mean motor United Huntington Disease Rating Scale, 18 ± 9) and 15 age- and sex-matched controls. We coupled (31)phosphorus nuclear magnetic resonance spectroscopy with activation of the occipital cortex in order to measure the relative concentrations of adenosine triphosphate, phosphocreatine, and inorganic phosphate before, during, and after visual stimulation. RESULTS: In controls, we observed an 11% increase in the inorganic phosphate/phosphocreatine ratio (P = .024) and a 13% increase in the inorganic phosphate/adenosine triphosphate ratio (P = .016) during brain activation, reflecting increased adenosine diphosphate concentrations. Subsequently, controls had a return to baseline levels during recovery (P = .012 and .022, respectively). In contrast, both ratios were unchanged in patients during and after visual stimulation. CONCLUSIONS: (31)Phosphorus nuclear magnetic resonance spectroscopy could provide functional biomarkers of brain energy deficit to monitor therapeutic efficacy in Huntington disease.
Authors: Xian-Feng Shi; Paul J Carlson; Tae-Suk Kim; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Seong-Eun Kim; Breanna Glaeser; Kristina Wang; Chun S Zuo; Eun-Kee Jeong; Perry F Renshaw; Douglas G Kondo Journal: Psychiatry Res Date: 2014-04-13 Impact factor: 3.222
Authors: Song Lou; Victoria C Lepak; Lynn E Eberly; Brian Roth; Weina Cui; Xiao-Hong Zhu; Gülin Öz; Janet M Dubinsky Journal: Hum Mol Genet Date: 2016-05-18 Impact factor: 6.150
Authors: Macarena Solís-Maldonado; María Paz Miró; Aníbal I Acuña; Adriana Covarrubias-Pinto; Anitsi Loaiza; Gonzalo Mayorga; Felipe A Beltrán; Carlos Cepeda; Michael S Levine; Ilona I Concha; Luis Federico Bátiz; Mónica A Carrasco; Maite A Castro Journal: CNS Neurosci Ther Date: 2018-04 Impact factor: 5.243
Authors: Peter Klinkmueller; Martin Kronenbuerger; Xinyuan Miao; Jee Bang; Kia E Ultz; Adrian Paez; Xiaoyu Zhang; Wenzhen Duan; Russell L Margolis; Peter Cm van Zijl; Christopher A Ross; Jun Hua Journal: J Cereb Blood Flow Metab Date: 2020-08-17 Impact factor: 6.200